Edgestream Partners L.P. Takes Position in Certara, Inc. (NASDAQ:CERT)

Edgestream Partners L.P. bought a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 152,159 shares of the company's stock, valued at approximately $1,782,000. Edgestream Partners L.P. owned approximately 0.09% of Certara as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CERT. Glenmede Trust Co. NA grew its position in Certara by 78.6% in the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company's stock valued at $14,123,000 after acquiring an additional 530,598 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Certara during the third quarter worth approximately $1,088,000. Advantage Alpha Capital Partners LP acquired a new stake in shares of Certara during the third quarter worth approximately $1,875,000. Brown Brothers Harriman & Co. acquired a new stake in shares of Certara during the third quarter worth approximately $27,292,000. Finally, Nicolet Advisory Services LLC grew its position in shares of Certara by 6.6% during the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock worth $273,000 after buying an additional 1,531 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Down 3.4 %

NASDAQ CERT traded down $0.38 during trading on Wednesday, reaching $10.88. 2,886,234 shares of the company's stock were exchanged, compared to its average volume of 817,847. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The firm has a market capitalization of $1.75 billion, a PE ratio of -54.40, a P/E/G ratio of 5.71 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company's fifty day simple moving average is $10.83 and its 200-day simple moving average is $12.91.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the company posted $0.06 EPS. Sell-side analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on CERT. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. Barclays cut their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. Finally, UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Certara currently has a consensus rating of "Hold" and an average target price of $15.92.

Insiders Place Their Bets

In related news, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company's stock, valued at $1,125,658.16. The trade was a 33.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.39% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.